Lupin

Homegrown pharma major Lupin on Wednesday posted a 22.19 per cent decline in consolidated net profit to Rs 1,155.30 crore in the September quarter, dragged down by an exceptional item. The company had posted a net profit of Rs 1,484.83 crore in the corresponding period of the previous fiscal year, it said in a regulatory filing to the exchanges. Revenue from operations was Rs 7,827.26 crore during the quarter under review, up from Rs 7,047.51 crore in the year-ago period, it said. Lupin's total expenses also rose to Rs 6,374.46 crore during the quarter from Rs 5,130.54 crore in the same period last year. During the April-September period in FY27, Lupin's net profit declined 4.95 per cent to Rs 2,572.28 crore from Rs 2,706.29 crore a year earlier, the filing said. During the six months ended September 30, 2026, Lupin Pharmaceuticals Inc USA, a wholly owned subsidiary of the Group, settled one of the ongoing antitrust matters for Rs 316.28 crore (USD 35.8 million) without admission

Benchmark indices traded lower for the third consecutive session on Thursday, as selling across sectors amid elevated crude oil prices and concerns over corporate earnings weighed on sentiment.

Formoflo-G MDI combines three established therapies in a twice-daily inhaler after DCGI approval, targeting India's large COPD patient pool

Anand James of Geojit Investments identified three stocks Lupin, Akums Drugs and Heritage Foods with a favourable technical set-up on charts at current levels.

The company plans to soon start the funding process for its oncology spin-off, Kaveri Therapeutics, which houses two specialised oncology programmes

When a stock becomes oversold, it does not automatically mean it is a good time to buy, cautions Pabitro Mukherjee, Deputy Vice President-Research at Bajaj Broking.

Sudeep Shah, Technical Research Analyst at SBI Securities, expects the bearish trend to continue in technically oversold stocks - Lupin, Godrej Consumer and PFC-and flags key hurdles to watch out for.

Siemens, Zydus Lifesciences, Bata India, Caliber Mining And Logistics, Delta Corp are among companies reporting earnings today.

In the past month, Lupin underperformed the market by falling 9 per cent, as against a 1.4 per cent gain in the BSE Sensex and a 2.6 per cent rally in the BSE Healthcare index.

Homegrown pharma major Lupin Ltd has reported a 16 per cent rise in consolidated profit after tax at Rs 1,416.98 crore in the first quarter ended June 30, riding on robust growth across its key markets. The company had posted a consolidated Profit After Tax (PAT) at Rs 1,221.46 crore in the corresponding period last fiscal, Lupin Ltd said in a regulatory filing on Thursday. Consolidated total revenue from operations in the first quarter was at Rs 8,276.89 crore as against Rs 6,268.34 crore in the year-ago period, it added. Total expenses in the quarter under review rose at Rs 6,389.83 crore as compared to Rs 4,931.84 crore in the corresponding period last fiscal, the company said. Commenting on the performance, Lupin Ltd Managing Director Nilesh Gupta said, "We are pleased to begin FY27 with a strong performance, driven by robust growth across our key markets and continued improvement in profitability." The company's focus on execution, operational excellence, and sustained ...

Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period

The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.

New company to raise capital for global clinical trials; Lupin to retain significant equity stake and provide seed funding

Pharma stock rally: Orchid Pharma, Hikal, Unichem Labs, IOL Chemicals, SPARC, RPG Life Sciences and Acutaas Chemicals surged up to 13% in Wednesday's trade.

In the past month, the Nifty Pharma index outperformed the market by surging 7.4 per cent, as compared to 4.2 per cent rise in the Nifty 50.

Stocks to Watch today, July 2, 2026: Hero MotoCorp, Tata Technologies, Medi Assist Healthcare, and NLC India are among the top stocks to remain in focus during today's trading session.

In the past seven trading days, the Nifty Pharma index outperformed the market by soaring 5.4 per cent, as compared to 0.1 per cent decline in the Nifty 50.

The tentative approval allows Lupin to market the generic prostate cancer treatment in the US after patent and exclusivity barriers expire

Lupin, Intas Pharmaceuticals, Sun Pharma, MSN Laboratories, Natco Pharma, Zydus Life Sciences and Dr Reddy's Laboratories are some of the companies, the note said, that could potentially benefit.

Stocks to Watch today, May 29, 2026: Ashok Leyland, Alkem Laboratories, PhysicsWallah, GMR Airports, InterGlobe Aviation, NMDC, and Glenmark Pharma are among the top stocks to remain in focus today